A retrospective study of the factors associated with hypercoagulability in the pediatric patients at a tertiary care children's hospital

Pediatric Critical Care Medicine

Volumn 9, Issue 5, 2008, Pages 511-516

  Slamon, Nicholas ^a   Krueger, Leslie J ^b   Edelson, Maureen ^b   Glutting, Joseph J ^b   Rittenhouse, David ^c  

^a UNIVERSITY OF FLORIDA   (United States)

^b NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Central venous catheter; Hypercoagulability; Pediatrics; Thrombosis

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTITHROMBIN III; APOLIPOPROTEIN A; BLOOD CLOTTING FACTOR 5 LEIDEN; HOMOCYSTEINE; PROTEIN C; PROTEIN S; PROTHROMBIN; BLOOD CLOTTING FACTOR 5; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2);

AGE DISTRIBUTION; ARTICLE; CENTRAL VENOUS CATHETER; CHILD; DISEASE ASSOCIATION; ELECTRONIC MEDICAL RECORD; GENE MUTATION; GENETIC PREDISPOSITION; HUMAN; HYPERCOAGULABILITY; HYPOTHESIS; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; PEDIATRIC HOSPITAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCHOOL CHILD; TERTIARY HEALTH CARE; THROMBOSIS; GENE FREQUENCY; GENETICS; HOSPITAL; MEDICAL AUDIT; PATHOPHYSIOLOGY; RISK FACTOR; STATISTICAL MODEL; STATISTICS; THROMBOPHILIA;

FACTOR V; GENE FREQUENCY; HOSPITALS, PEDIATRIC; HUMANS; LOGISTIC MODELS; MEDICAL AUDIT; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MODELS, STATISTICAL; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; THROMBOPHILIA; THROMBOSIS;

EID: 60849128563     PISSN: 15297535     EISSN: None     Source Type: Journal    
DOI: 10.1097/PCC.0b013e3181849dfe     Document Type: Article

References (25)

1. Hoppe C, Matsunaga A: Pediatric thrombosis. Pediatr Clin North Am 2002; 49:1257-1283
2. Andrew M, David M, Adams M, et al: Venous thromboembolic complications (VTE) in children: First analyses of the Canadian Registry of VTE. Blood 1994; 83:1251-1257
3. van Ommen CH, Heijboer H, Baler HR, et al: Venous thromboembolism in childhood: A prospective two-year registry in the Netherlands. J Pediatr 2001; 139:676-681
4. Nowak-Gottl U, von Kries R, Gobel U: Neonatal symptomatic thromboembolism in Germany: two-year survey. Arch Dis Child Fetal Neonatal Ed 1997; 76:F163-F167
5. Stein PD, Kayali F, Olsen RE: Incidence of venous thromboembolism in infants and children: Data from the National Hospital Discharge Survey. J Pediatr 2004; 145: 563-565
6. Andrew M: Relevance to newborns and infants. In: Nathan and Oski's Hematology of Infancy and Childhood, 5th Ed. Nathan D, Orkin SH (Eds). Philadelphia, WB Saunders, 1998, pp 155-157
7. Heller C, Schobess R, Kurnik K, et al: Abdominal venous thrombosis in neonates and infants: Role of prothrombotic risk factors-A multicenter case control study. For the Childhood Thombophilia Study Group. Br J Haematol 2000; 111:534-539
8. Male C, Chait P, Andrew M, et al: Central venous line-related thrombosis in children: Association with central venous line location and insertion technique. Blood 2003; 101: 4273-4278
9. Monagle P, Michelson AD, Bovill E, et al: Antithrombotic therapy in children. Chest 2001; 119:344S-370S
10. Tabachnick BG, Fidell LS: Using multivariate statistics. 5th Ed. New York, Harper Collins Publishers, 2007
11. Hosmer DW, Lemeshow S: Applied logistic regression. New York, Wiley, 1989
12. Nagelkerke NJD: A note on a general defini-tion of the coefficient of determination. Bi-ometrika 1991; 78:691-692
13. Greaves M, Baglin T: Laboratory testing for heritable thrombophilia: Impact on clinical management of thrombotic disease. Br J Haemtol 2000; 109:699-703
14. Salomon O, Steinberg DM, Zivelin A, et al: Single and combined prothrombotic factors in patients with idiopathic venous thrombo-embolism: Prevalence and risk assessment. Arterioscler Thromb Vasc Biol 1999; 19: 511-518
15. Morange PE, Henry M, Tregouet D, et al: The A-844G polymorphism in the PAI-1 gene is associated with a higher risk of venous thrombosis in factor V Leiden carriers. Arte-rioscler Thromb Vasc Biol 2000; 101: 317-319
16. DeStefano V, Martinelli I, Mannucci P, et al: The risk of recurrent deep venous thrombosis among heterozygous carriers of both fac- tor V Leiden and the G20210A prothrombin mutation. N Engl J Med 1999; 341:801-806
17. Kluijtmans L, Boers G, Verbruggen B, et al: Homozygous cystathionine beta-synthase de-ficiency, combined with factor V Leiden or thermolabile MTHFR in the risk of venous thrombosis. Blood 1998; 91:2015-2018
18. Madonna P, Piemontino U, De Stefano V, et al: Coexistence of thrombophilic gene polymorphisms among 559 unrelated consecutive patients with a history of thrombosis. Thromb Res 2001; 101:317-319
19. Vandenbroucke J, Koster T, Briet E, et al: Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-1457
20. McColl M, Walker I: The role of inherited thrombophilia in venous thromboembolism associated with pregnancy. Br J Obstet Gynaecol 1999; 106:756-766
21. Lowe G, Haverkate F, Thompson S, et al: Prediction of deep vein thrombosis after elective hip replacement surgery by preoperative clinical and hemostatic variables: The ECAT DVT study. European Concerted Action on Thrombosis. Thromb Haemost 1999; 81: 879-886
22. Monagle R, Chan A, Massicotte P, et al: An-tithrombotic therapy in children: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 645S-687S
23. Dellinger RP, Carlet J, Masur H, et al: Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004; 32:858-873 (Pubitemid 38344143)
24. Dix D, Andrew M: The use of low molecular weight heparin in pediatric patients: A prospective cohort study. J Pediatr 2000; 136: 439-445
25. Massicotte P, Julian J, Gent M, et al: An open label randomized controlled trial of low molecular weight heparin for the prevention of central venous line related thrombotic complications in children: The PROTEKT trial. Thromb Res 2003; 109:101-108